• RxStrategies Clinical Insights – January 2015, Issue 1

    Welcome to the January edition of RxStrategies Clinical Insights, a concise communication to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approvals Savaysa™ (edoxaban tablets) January 8, 2015 — The U.S. Food and Drug Administration approved the anti-clotting drug Savaysa™ (edoxaban tablets) to reduce the risk of… Read more »

  • RxStrategies Clinical Insights – December 2014, Issue 1

    Welcome to the December edition of RxStrategies Clinical Insights, a concise communication to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Blincyto™ (blinatumomab) December 3, 2014 – The U.S. Food and Drug Administration approved Blincyto™(blinatumomab) to treat patients with Philadelphia chromosome-negative precursor B-cell acute… Read more »

  • December 340B Insider

    340B Winter Coalition Conference Mark your calendars for the 11th Annual 340B Coalition Winter Conference, from Feb. 4 to 6, 2015 at the Hyatt Regency Embarcadero in San Francisco. RxStrategies invites you to schedule a meeting time or stop by our booth #18-19 in the exhibit hall. Our team will greet you and answer any… Read more »

  • RxStrategies Clinical Insights – November 2014, Issue 2

    Welcome to the second November edition of RxStrategies Clinical Insights, a concise communication to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approvals Lemtrada™ (alemtuzumab) November 14, 2014—The U.S. Food and Drug Administration has approved Lemtrada™ (alemtuzumab) as a disease-modifying therapy for people with relapsing forms of Multiple… Read more »

  • RxStrategies Clinical Insights – October 2014, Issue 1

    New Drug Approvals Esbriet® (pirfenidone), Ofev® (nintedanib)– New Drug Approval (Orphan Drug) October 15, 2014 – The U.S. Food and Drug Administration announced the approval of Esbriet® (pirfenidone) and Ofev® (nintedanib) for the treatment of idiopathic pulmonary fibrosis (IPF). IPF is a condition in which the lungs become progressively scarred over time. As a result,… Read more »

  • RxStrategies Clinical Insights – September 2014, Issue 2

    Welcome to this month’s second edition of RxStrategies Clinical Insights, a concise communication to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.    New Drug Approvals Trulicity™ (dulaglutide) – New Drug Approval September 18, 2014 – The U.S. Food and Drug Administration approved Trulicity™ (dulaglutide), a once-weekly subcutaneous injection to improve… Read more »

  • September 340B Insider

    RxStrategies Updates RxStrategies is pleased to introduce the newest member of our team. Rhodie Smith has joined the RxS team as National Sales Manager. Rhodie brings over eight years of experience working with the 340B program, as well as extensive knowledge of PBMs and health care. He began his tenure with RxS on Sept. 1,… Read more »

  • RxStrategies Clinical Insights – September 2014, Issue 1

    Welcome to this month’s RxStrategies Clinical Insights, a concise communication to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approvals Keytruda® (pembrolizumab) – New Orphan Drug Approval September 4, 2014 – The U.S. Food and Drug Administration approvedKeytruda® (pembrolizumab) for treatment of patients with advanced or unresectable… Read more »

  • RxStrategies, Inc. Names Rhodie Smith National Sales Manager

    BOCA RATON, Florida, September 4, 2014-RxStrategies, Inc. is pleased to announce the appointment of Rhodie Smith to National Sales Manager. In this new role, Rhodie joins the RxStrategies’ senior leadership team and is responsible for sales and delivery of customized 340B pharmacy administration and split billing solutions to the growing 340B marketplace. “I am very… Read more »

  • RxStrategies Clinical Insights – August 2014

     Download print version. Welcome to this month’s RxStrategies Clinical Insights, a concise communication to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approvals Cerdelga™ (eliglustat) – New Orphan Drug Approval August 19, 2014 – The U.S. Food and Drug Administration approved Cerdelga™ (eliglustat) for the long-term treatment of… Read more »